Study identifier:D133FR00178
ClinicalTrials.gov identifier:NCT05817110
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence defined Lung Nodule Malignancy Score in Patients with Pulmonary Nodule Multicentric, multinational, prospective, observational study.
Lung Malignancy
N/A
No
-
All
700
Observational
35 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Screening
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Other: Computed tomography Cohort In case of any nodule detection by qXR, it will be classified either as low-risk LNMS(lung nodule malignancy score ) or high-risk LNMS confirmed by radiologist. The patient will be requested to get a CT scan after enrolment in the study. | - |